Stocksigma LogoStocksigma Logo

Emcure Pharmaceuticals Reports Strong Q2 FY27 Results and Raises Full-Year Revenue Guidance

Emcure Pharmaceuticals reported Q2 FY27 revenue growth of 24.3% YoY to INR2,820 crores, with EBITDA rising 31% YoY to INR575 crores as margins expanded 100

Emcure Pharmaceuticals Reports Strong Q2 FY27 Results and Raises Full-Year Revenue Guidance

Emcure Pharmaceuticals Ltd · Transcript · 06 Nov 2026, 10:17 pm

Emcure Pharmaceuticals Reports Strong Q2 FY27 Results and Raises Full-Year Revenue Guidance Emcure Pharmaceuticals reported Q2 FY27 revenue growth of 24.3% YoY to INR2,820 crores, with EBITDA rising 31% YoY to INR575 crores as margins expanded 100 bps YoY to 20.4%. PAT increased 29% YoY to INR325 crores. Growth was driven by international markets, up 34.5% YoY to INR1,665 crores (59% of revenue), while India grew 12% YoY to INR1,155 crores. Following strong 1H performance, management raised full-year FY27 revenue guidance to above 20% YoY and expects EBITDA margin improvement at the upper end of 75–100 bps.

Original exchange filing (PDF)

More announcements from Emcure Pharmaceuticals Ltd

All Emcure Pharmaceuticals Ltd announcements